# Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC

> **NCT06467799** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 39 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Beyond Milan Criteria

## Interventions

- **DRUG:** Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1

## Key facts

- **NCT ID:** NCT06467799
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2027-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06467799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06467799, "Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06467799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*